Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16090776 | 0.88 | KDM4E (0.33) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL16090780 | 0.80 | CNR2 (0.33) | PGR | |
| SCHEMBL16090778 | 0.80 | KMT2A (0.41) | BRPF1SMARCA2CYP2A6ARPGR | |
| SCHEMBL16090792 | 0.75 | MEN1 (0.35) | — | |
| SCHEMBL18256193 | 0.74 | CCR2 (0.32) | — | |
| SCHEMBL9124674 | 0.72 | ALOX5 (0.42) | BRPF1KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL16090766 | 0.71 | PARG (0.36) | CYP2A6PGRKDM4EALDH1A1TSHR | |
| SCHEMBL31702496 | 0.71 | HRH3 (0.37) | HRH3KDM4E | |
| SCHEMBL24392772 | 0.70 | KDM4E (0.40) | BRPF1CYP2A6ARKDM4EALDH1A1 | |
| SCHEMBL16030138 | 0.70 | NR1H2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2017-09-07 | — | — | US | disclosed |
| US-9505782-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505782-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505781-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-9505781-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-02-18 | — | — | US | disclosed |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE LEUKEMIA & LYMPHOMA SOCIETY, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216993-B2 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-12-22 | — | — | US | disclosed |
| WO-2014164543-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275070-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | BRPF1 1008/4885SMARCA2 148/4885CYP2A6 3258/4885 |
| US-20160046647-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | BRPF1 942/4885SMARCA2 154/4885CYP2A6 3214/4885 |
| US-20170253611-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | BRPF1 1105/4885SMARCA2 251/4885CYP2A6 2327/4885 |
| US-20160137665-A1 | COMPOSITIONS COMPRISING THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | MLLT1, MLLT3, BMI1 | BRPF1 1057/4885SMARCA2 203/4885CYP2A6 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.